Search

This article has a correction concerning the authors: We regret that there is an error with the author list in our original article. The authors Jussi Helminen, Paulus Hyväri, and Ilkka Kilpeläinen, all with the Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland, were mistakenly omitted. The author list should be as shown above in this Addition and Correction. DOI 10.1021/acssuschemeng.0c07773 Ioncell is a Lyocell based technology for the production of manmade cellulose fibers. This technology exploits the intrinsic dissolution power of superbase-based ionic liquids (ILs) toward cellulose and the ability to form spinnable cellulose solutions. The regenerated fibers are produced via a dry-jet wet spinning process in which the cellulose filaments are stretched in an air gap before regenerating in an aqueous coagulation medium. For the commercialization of this process, it is essential to demonstrate the quantitative recovery of the solvent from the coagulation bath without impairing its solvation power. This study reports on the spinnability and recyclability of the IL 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-enium acetate ([mTBDH][OAc]) over five cycles in comparison to 1,5-diaza-bicyclo[4.3.0]non-5-enium acetate ([DBNH][OAc]). The aqueous IL solutions were recovered from the coagulation bath by successive thermal treatments under reduced pressure. Accordingly, the recycled ILs were utilized to dissolve 13 wt % cellulose pulp in each cycle without the addition of make-up IL. While using [mTBDH][OAc], the pulp was completely dissolved and processed into easily spinnable cellulose solutions during all five cycles, whereas the ability to dissolve pulp was completely lost after the first recovery cycle when using [DBNH][OAc]. The composition of the recovered ILs and extent of side-products generated in the adopted process was analyzed in detail. This includes characterization of the rheological properties of the solutions as well as the macromolecular and mechanical properties of the regenerated fibers. In addition, we review the toxicity of both solvents using Vibrio fischeri bacteria. Finally, the spun fibers from all [mTBDH][OAc] spinning trials were combined to produce a demonstration dress (Paju), designed and sewn by Marimekko Design House in Finland.

STUDY QUESTION We aim to develop, disseminate and implement a minimum data set, known as a core outcome set, for future male infertility research. WHAT IS KNOWN ALREADY Research into male infertility can be challenging to design, conduct and report. Evidence from randomized trials can be difficult to interpret and of limited ability to inform clinical practice for numerous reasons. These may include complex issues, such as variation in outcome measures and outcome reporting bias, as well as failure to consider the perspectives of men and their partners with lived experience of fertility problems. Previously, the Core Outcome Measure for Infertility Trials (COMMIT) initiative, an international consortium of researchers, healthcare professionals and people with fertility problems, has developed a core outcome set for general infertility research. Now, a bespoke core outcome set for male infertility is required to address the unique challenges pertinent to male infertility research. STUDY DESIGN, SIZE, DURATION Stakeholders, including healthcare professionals, allied healthcare professionals, scientists, researchers and people with fertility problems, will be invited to participate. Formal consensus science methods will be used, including the modified Delphi method, modified Nominal Group Technique and the National Institutes of Health’s consensus development conference. PARTICIPANTS/MATERIALS, SETTING, METHODS An international steering group, including the relevant stakeholders outlined above, has been established to guide the development of this core outcome set. Possible core outcomes will be identified by undertaking a systematic review of randomized controlled trials evaluating potential treatments for male factor infertility. These outcomes will be entered into a modified Delphi method. Repeated reflection and re-scoring should promote convergence towards consensus outcomes, which will be prioritized during a consensus development meeting to identify a final core outcome set. We will establish standardized definitions and recommend high-quality measurement instruments for individual core outcomes. STUDY FUNDING/COMPETING INTEREST(S) This work has been supported by the Urology Foundation small project award, 2021. C.L.R.B. is the recipient of a BMGF grant and received consultancy fees from Exscentia and Exceed sperm testing, paid to the University of Dundee and speaking fees or honoraria paid personally by Ferring, Copper Surgical and RBMO. S.B. received royalties from Cambridge University Press, Speaker honoraria for Obstetrical and Gynaecological Society of Singapore, Merk SMART Masterclass and Merk FERRING Forum, paid to the University of Aberdeen. Payment for leadership roles within NHS Grampian, previously paid to self, now paid to University of Aberdeen. An Honorarium is received as Editor in Chief of Human Reproduction Open. M.L.E. is an advisor to the companies Hannah and Ro. B.W.M. received an investigator grant from the NHMRC, No: GNT1176437 is a paid consultant for ObsEva and has received research funding from Ferring and Merck. R.R.H. received royalties from Elsevier for a book, consultancy fees from Glyciome, and presentation fees from GryNumber Health and Aytu Bioscience. Aytu Bioscience also funded MiOXYS systems and sensors. Attendance at Fertility 2020 and Roadshow South Africa by Ralf Henkel was funded by LogixX Pharma Ltd. R.R.H. is also Editor in Chief of Andrologia and has been an employee of LogixX Pharma Ltd. since 2020. M.S.K. is an associate editor with Human Reproduction Open. K.Mc.E. received an honoraria for lectures from Bayer and Pharmasure in 2019 and payment for an ESHRE grant review in 2019. His attendance at ESHRE 2019 and AUA 2019 was sponsored by Pharmasure and Bayer, respectively. The remaining authors declare no competing interests. TRIAL REGISTRATION NUMBER Core Outcome Measures in Effectiveness Trials (COMET) initiative registration No: 1586. Available at www.comet-initiative.org/Studies/Details/1586. TRIAL REGISTRATION DATE N/A. DATE OF FIRST PATIENT’S ENROLMENT N/A.

Purpose of the review: We aim to review the methods, current research evidence, and future directions in body composition analysis (BCA) with CT imaging. Recent findings: CT images can be used to evaluate muscle tissue, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) compartments. Manual and semiautomatic segmentation methods are still the gold standards. The segmentation of skeletal muscle tissue and VAT and SAT compartments is most often performed at the level of the 3rd lumbar vertebra. A decreased amount of CT-determined skeletal muscle mass is a marker of impaired survival in many patient populations, including patients with most types of cancer, some surgical patients, and those admitted to the intensive care unit (ICU). Patients with increased VAT are more susceptible to impaired survival / worse outcomes; however, those patients who are critically ill or admitted to the ICU or who will undergo surgery appear to be exceptions. The independent significance of SAT is less well established. Recently, the roles of the CT-determined decrease of muscle mass and increased VAT area and epicardial adipose tissue (EAT) volume have been shown to predict a more debilitating course of illness in patients suffering from severe acute respiratory syndrome coronavirus 2 (COVID-19) infection. The field of CT-based body composition analysis is rapidly evolving and shows great potential for clinical implementation. publishedVersion